Kilitch Drugs (India)NSE:KILITCH -2.89%84 Piotroski F-Score is 2 as of Jun. 28, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹232.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 978 Drug Manufacturers companies, Kilitch Drugs (India) ranks worse than 91.31% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kilitch Drugs (India) has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Kilitch Drugs (India)'s Piotroski F-Score or its related term are showing as below:
NSE:KILITCH'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 6 Max: 7
Current: 2
During the past 13 years, the highest Piotroski F-Score of Kilitch Drugs (India) was 7. The lowest was 2. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Kilitch Drugs (India) Piotroski F-Score Related Terms
Kilitch Drugs (India) Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kilitch Drugs (India)'s current Net Income (TTM) was 302.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Kilitch Drugs (India)'s return on assets of this year was 0.09644489. Kilitch Drugs (India)'s return on assets of last year was 0.11122395.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Kilitch Drugs (India)'s gearing of this year was 0.15211159. Kilitch Drugs (India)'s gearing of last year was 0.10046353.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Kilitch Drugs (India)'s current ratio of this year was 1.82727436. Kilitch Drugs (India)'s current ratio of last year was 2.06281928.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Kilitch Drugs (India)'s number of shares in issue this year was 33.857. Kilitch Drugs (India)'s number of shares in issue last year was 32.868.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Kilitch Drugs (India)'s gross margin of this year was 0.46434546. Kilitch Drugs (India)'s gross margin of last year was 0.47266745.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Kilitch Drugs (India)'s asset turnover of this year was 0.75283598. Kilitch Drugs (India)'s asset turnover of last year was 0.82611505.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
0
+
0
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kilitch Drugs (India) has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Kilitch Drugs (India) (NSE:KILITCH) has a Piotroski F-Score of 2 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kilitch Drugs (India) and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Kilitch Drugs (India)'s Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Kilitch Drugs (India) ranks #893 out of 978 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is Kilitch Drugs (India)'s Piotroski F-Score too high?
Kilitch Drugs (India)'s current Piotroski F-Score of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Kilitch Drugs (India)'s value of 2 is 60% below this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #893 out of 978 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #893 out of 978 companies for Piotroski F-Score. This places Kilitch Drugs (India) in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Kilitch Drugs (India)'s value of 2 is 60% below this benchmark. Historically, Kilitch Drugs (India)'s own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Kilitch Drugs (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current Piotroski F-Score is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹232.78, compared to a current price of ₹185.31 — trading 20.4% below its estimated fair value. The current Piotroski F-Score is 2, which is 67% below median its 10-year median of 6.00 and 60% below the Drug Manufacturers industry median of 5.00. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Piotroski F-Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹185.31 is trading 20.4% below its estimated GF Value™ of ₹232.78.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Piotroski F-Score: 2 (67% below median its 10-year median of 6.00)
GF Value™: ₹232.78 vs. price of ₹185.31 (20.4% below fair value)
Industry Position: 60% below the Drug Manufacturers median (#893 of 978)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score
Get the complete analysis for NSE:KILITCH
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
